Appeal No. 1999-1703
Application No. 08/313,194
Claims 1 and 13 are illustrative of the claims on appeal and read as follows:
1. A method of treating or preventing the development of disease conditions
associated with impaired neuronal conduction velocity in a warm-blooded animal requiring
such treatment which comprises administering to said animal a neuronal conduction
velocity enhancing effective amount of an angiotensin II antagonist, or a pharmaceutically
acceptable salt thereof.
13. A pharmaceutical composition comprising an angiotensin II antagonist, or a
pharmaceutically acceptable salt thereof, together with one or more pharmaceutical agents
selected from aldose reductase inhibitors and hypoglycaemic agents.
The prior art reference relied upon by the examiner is:
Bagley et al (Bagley) 5,175,164 Dec. 29, 1992
References relied on by Appellants:
Wyngaarden et al. (Wyngaarden), Textbook of Medicine, Chpt. 218, Diabetes Mellitus, pp.
1307-1309 and 2037-2038. (Date unknown)
Weatherall et al. (Weatherall), Oxford Textbook of Medicine, pp. 3972 and 3993, Oxford
Press, New York (1996)
Bartus et al. (Bartus), “The Cholinergic Hypothesis of Geriatric Memory Dysfunction,”
Science, Vol. 217, pp. 408-417 (1982)
th
Collins et al. (Collins), Gray's Anatomy, 38 Ed., Churchill Livingston Pub., pp. 18 and
1819 and 1820 (1995)
Ground of Rejection
Claims 1-5 and 13 stand rejected under 35 U.S.C. § 103(a) as obvious over
applicants' admissions (specification pages 1-3) in view of Bagley.
2
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 Next
Last modified: November 3, 2007